SMAD2 and urinary bladder carcinoma: Our results indicate that the TGFβ-Smad2/3 signaling pathway-induced EMT process is involved in GCB resistance in bladder cancer by transactivating Slug and ZEB2 and downregulating hCNT1 and hENT1.